María-Victoria Mateos first talks about the emergence of measurable residual disease (MRD) as a possible surrogate marker for clinical outcome, or even for cure, in newly diagnosed multiple myeloma. She goes on to discuss the importance of autologous stem cell transplantation (auto-SCT) and its success in treating newly diagnosed patients. But despite this, in 2020, there have been preliminary findings suggesting that auto-SCT could be delayed or skipped in certain patients. María-Victoria Mateos concludes by mentioning bispecific antibodies and CAR T cells. In the future, these may be used in earlier stages of myeloma treatment and come to challenge the use of auto-SCT.